Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab plus adjuvant chemotherapy vs chemotherapy in stage II–III TNBC
CTR20182046Phase 3Terminated
- Sponsor
- Roche
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by Roche. Started Feb 2019; status: terminated.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20182046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182046.